Hepatitis Interactions Presentations at CROI
18th Conference on Retroviruses and Opportunistic Infections, Boston, Feb/Mar 2011.
Over 4,000 leading researchers and clinicians from around the world met in Boston for the 18th Conference on Retroviruses and Opportunistic Infections (CROI). CROI is a scientifically focused meeting of the world’s leading researchers working to understand, prevent, and treat HIV/AIDS and its complications. The goal of CROI is to provide a forum for translating laboratory and clinical research into progress against the AIDS epidemic. However there is an emerging interest within the meeting of hepatitis and three abstracts were presented on interactions with the HCV protease inhibitors boceprevir and telaprevir.
- Clinical pharmacology of boceprevir: metabolism, excretion, and drug-drug interactions (abstract 118).
- Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor telaprevir in healthy volunteers (abstract 119).
- Low dose ritonavir and the pharmacokinetics of the investigational HCV protease inhibitor telaprevir in healthy volunteers (abstract 629).
Data from these abstracts are summarised in meeting report (see link below). Two of the three abstracts (118 and 119) were oral presentations and the webcasts can be accessed by clicking here (select "Tuesday" and scroll to "Oral Abstracts: HCV pathogenesis ..."). Note the boceprevir presentation starts at 01:33:17 and the telaprevir presentation follows at 01:46:56.